US 10465194
Complement component iRNA compositions and methods of use thereof
granted A61KA61K31/713A61K38/12
Quick answer
US patent 10465194 (Complement component iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/713, A61K38/12, A61K39/3955, A61P